Dr Reddy’s Laboratories launched Peg-grafeel, Dr Reddy’s brand of pegfilgrastim in India. Peg-grafeel has been approved in India to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy with the exception of chronic myeloid leukaemia and myelodysplastic syndromes.
Pegfilgrastim is a pegylated long-lasting variant of filgrastim. One injection of pegfilgrastim can replace up to 14 injections of filgrastim, which must be administered daily. It can be administered once per chemotherapy cycle, providing convenience to the patient while eliminating many of the additional costs of treatment.
Peg-grafeel is priced at an MRP of Rs.8,865 and represents a breakthrough in the pricing of this complex molecule. It is priced at approximately 25 per cent of the originator brand in India, and is priced 95 per cent lower than the US price for pegfilgrastim
Manufacturer: Dr Reddy